Methotrexate 500mg/20mL
Product Overview
| Generic Name | Methotrexate 500mg/20mL |
| Brand Name(s) | Rheumatrex, Trexall |
| Category | Antineoplastic / Cancer |
| Form | intravenous/intramuscular/subcutaneous injection |
| Strength | 500 mg / 20 mL |
| Therapeutic Class | Antimetabolite; folic acid analogue with immunosuppressant & antineoplastic activity |
| ATC Code | L01BA01 |
Manufacturing & Regulatory
| Manufacturer | Actavis, Teva |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II |
| COFEPRIS | Batch-specific |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | Upon Request |
Special Notes
Indications and Usage – Methotrexate 500mg Methotrexate 500mg is indicated for the treatment of certain cancers, including breast cancer, lung cancer, head and neck cancers, and advanced-stage trophoblastic neoplasms. It is also used in high-dose regimens for osteosarcoma and as part of combination chemotherapy protocols.